Please login to the form below

Not currently logged in
Email:
Password:

GSK refocuses MS drug development

GlaxoSmithKline has decided to refocus development efforts for MS drug ofatumumab on an injectable rather than an intravenous formulation

GlaxoSmithKline (GSK) has decided to refocus development efforts for ofatumumab, a human monoclonal antibody being tested for multiple sclerosis (MS) and other autoimmune indications, on an injectable rather than an intravenous formulation. This is in order to maximise convenience and tolerability for patients.

GSK and the Danish firm Genmab restructured their collaborative agreement for the drug this summer in order to give GSK development responsibility for autoimmune indications. Following that change, GSK reviewed the development strategy and determined that it should focus on the subcutaneous delivery of ofatumumab in autoimmune indications.

GSK said it will stop development of the intravenous version in autoimmune disease in spite of clinical data showing efficacy for the formulation in MS and rheumatoid arthritis.

Earlier this month, the companies released positive phase I/II study data for ofatumumab in MS. GSK plans to begin a phase IIb dose ranging study in MS using the subcutaneous formulation next year. Further development of the subcutaneous drug in rheumatoid arthritis is under review, the company said.

The two companies continue to be jointly responsible for the development of an intravenous formulation of the product for oncology indications. A phase II trial of ofatumumab in combination with bendamustine in patients with indolent B-cell non-Hodgkin's lymphoma was initiated in early September.

16th September 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics